
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Concern that gene and stem-cell research could lead to human cloning has generated proposals for legislative bans, which could block promising research.
over 25 years ago
Policy: Task Mastersover 25 years ago
Pharmacia's Carrie Cox: HBA Woman of the Yearover 25 years ago
Friends of Complexityover 25 years ago
Under Federal Fireover 25 years ago
Task Force: Enter the Fixersover 25 years ago
The Next Y2K





